TNF and liver cancer: Both anti-CD8–anti-PD1 and anti-TNF–anti-PD1 antibody treatments ameliorated liver damage, liver pathology and liver inflammation (Fig. 2g, Extended Data Fig. 7), and decreased the incidence of liver cancer compared to anti-PD1 treatment alone (Fig. 2i).